About: Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1016/j.clbc.2011.03.001
Description	Adjuvant trastuzumab (AT) is known to significantly improve survival of women with HER2(+) early breast cancer. This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant population, within a routine clinical setting. Histopathology reports of invasive breast cancer resected at Imperial College Healthcare NHS Trust (ICHT) between January 2006 and December 2008 were reviewed. HER2(+) patients were identified and their case notes reviewed. In addition, patients who received AT at our center but underwent surgery elsewhere were included in the efficacy and safety analyses. The local HER2(+) rate was 13.1%, with 54.5% of these patients receiving AT. A total of 128 patients received AT (85 local and 43 referrals from elsewhere). Neoadjuvant chemotherapy (CT) followed by postoperative AT was associated with a significantly increased risk of recurrence compared with adjuvant CT and then AT (hazard ratio [HR] 18.6 [95% CI, 1.8-152.2]; P = .013). Adjuvant trastuzumab (AT) is known to significantly improve survival of women with HER2(+) early breast cancer. This study explores the use and nonuse of AT in early breast cancer, as well as the efficacy in a neoadjuvant and adjuvant population, within a routine clinical setting. Histopathology reports of invasive breast cancer resected at Imperial College Healthcare NHS Trust (ICHT) between January 2006 and December 2008 were reviewed. HER2(+) patients were identified and their case notes reviewed. In addition, patients who received AT at our center but underwent surgery elsewhere were included in the efficacy and safety analyses. The local HER2(+) rate was 13.1%, with 54.5% of these patients receiving AT. A total of 128 patients received AT (85 local and 43 referrals from elsewhere). Neoadjuvant chemotherapy (CT) followed by postoperative AT was associated with a significantly increased risk of recurrence compared with adjuvant CT and then AT (hazard ratio [HR] 18.6 [95% CI, 1.8-152.2]; P = .013). (en)
Title	Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era (en)
skos:prefLabel	Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era (en)
skos:notation	RIV/00216208:11120/11:00003515!RIV12-MSM-11120___
http://linked.open...avai/predkladatel	3. lékařská fakulta
http://linked.open...avai/riv/aktivita	I S
http://linked.open...avai/riv/aktivity	I, S
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2012
http://linked.open...aciTvurceVysledku	Gojiš, Ondřej
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Karlova v Praze / 3. lékařská fakulta
http://linked.open...dnocenehoVysledku	210374
http://linked.open...ai/riv/idVysledku	RIV/00216208:11120/11:00003515
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	Breast; Trastuzumab; Untreated; Neoadjuvant; Adjuvant (en)
http://linked.open.../riv/klicoveSlovo	Breast Neoadjuvant Untreated Adjuvant Trastuzumab
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[E044C312C6E9]
http://linked.open...i/riv/nazevZdroje	Clinical Breast Cancer
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	1 (xsd:int)
http://linked.open...cetTvurcuVysledku	17 (xsd:int)
http://linked.open...UplatneniVysledku	2011
http://linked.open...v/svazekPeriodika	11
http://linked.open...iv/tvurceVysledku	Gojiš, Ondřej Palmieri, Carlo
http://linked.open...ain/vavai/riv/wos	000291328500003
issn	1526-8209
number of pages	10 (xsd:int)
http://bibframe.org/vocab/doi	10.1016/j.clbc.2011.03.001
http://localhost/t...ganizacniJednotka	11120
is http://linked.open...avai/riv/vysledek of	Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 82 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software